In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a ...
Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...